The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia

被引：35

作者：

Brown, Jennifer R. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02215 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2011年

关键词：

STEM-CELL TRANSPLANTATION; HIGH-DOSE METHYLPREDNISOLONE; TERM-FOLLOW-UP; MARROW-TRANSPLANTATION; ALEMTUZUMAB CAMPATH-1H; CLINICAL-EFFICACY; EFFECTIVE THERAPY; SALVAGE THERAPY; POOR-PROGNOSIS; FLUDARABINE;

D O I：

10.1182/asheducation-2011.1.110

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Despite the widespread use of highly effective chemoimmunotherapy (CIT), fludarabine-refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical problem associated with poor overall survival (OS). The traditional definition, which includes those patients with no response or relapse within 6 months of fludarabine, is evolving with the recognition that even patients with longer remissions of up to several years after CIT have poor subsequent treatment response and survival. Approved therapeutic options for these patients remain limited, and the goal of therapy for physically fit patients is often to achieve adequate cytoreduction to proceed to allogeneic stem cell transplantation (alloSCT). Fortunately, several novel targeted therapeutics in clinical trials hold promise of significant benefit for this patient population. This review discusses the activity of available and novel therapeutics in fludarabine-refractory or fludarabine-resistant CLL as well as recently updated data on alloSCT in CLL.

引用

页码：110 / 118

页数：9

共 66 条

[31]

Jaglowski SM, 2010, BLOOD, V116, P2383

[32] Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia [J].

Keating, Michael J. ;

Wierda, William G. ;

Tam, Constantine S. ;

Lynn, Alice ;

O'Brien, Susan ;

Lerner, Susan ;

Kantarjian, Hagop M. .

BLOOD, 2009, 114 (22) :940-941

[33] Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy [J].

Keating, MJ ;

O'Brien, S ;

Lerner, S ;

Koller, C ;

Beran, M ;

Robertson, LE ;

Freireich, EJ ;

Estey, E ;

Kantarjian, H .

BLOOD, 1998, 92 (04) :1165-1171

[34] Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study [J].

Keating, MJ ;

Flinn, I ;

Jain, V ;

Binet, JL ;

Hillmen, P ;

Byrd, J ;

Albitar, M ;

Brettman, L ;

Santabarbara, P ;

Wacker, B ;

Rai, KR .

BLOOD, 2002, 99 (10) :3554-3561

[35] Results of first salvage therapy for patients refractory to a fluidarabine regimen in chronic lymphocytic leukemia [J].

Keating, MJ ;

O'Brien, S ;

Kontoyiannis, D ;

Plunkett, W ;

Koller, C ;

Beran, A ;

Lerner, S ;

Kantarjian, H .

LEUKEMIA & LYMPHOMA, 2002, 43 (09) :1755-1762

[36] AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - PRELIMINARY-RESULTS [J].

KHOURI, IF ;

KEATING, MJ ;

VRIESENDORP, HM ;

READING, CL ;

PRZEPIORKA, D ;

HUH, YO ;

ANDERSSON, BS ;

VANBESIEN, KW ;

MEHRA, RC ;

GIRALT, SA ;

IPPOLITI, C ;

MARSHALL, M ;

THOMAS, MW ;

OBRIEN, S ;

ROBERTSON, LE ;

DEISSEROTH, AB ;

CHAMPLIN, RE .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :748-758

[37] Nonmyeloablative Allogeneic Stem Cell Transplantation in Relapsed/Refractory Chronic Lymphocytic Leukemia Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome [J].

Khouri, Issa F. ;

Bassett, Roland ;

Poindexter, Nancy ;

O'Brien, Susan ;

Bueso-Ramos, Carlos E. ;

Hsu, Yvonne ;

Ferrajoli, Alessandra ;

Keating, Michael J. ;

Champlin, Richard ;

Fernandez-Vina, Marcelo .

CANCER, 2011, 117 (20) :4679-4688

[38] Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL [J].

Lanasa, Mark C. ;

Andritsos, Leslie ;

Brown, Jennifer R. ;

Gabrilove, Janice ;

Caligaris-Cappio, Federico ;

Larson, Richard ;

Kipps, Thomas J. ;

Leblond, Veronique ;

Milligan, Donald ;

Janssens, Ann ;

Heerema, Nyla A. ;

Stilgenbauer, Stephan ;

Byrd, John C. ;

Grever, Michael R. .

BLOOD, 2010, 116 (21) :32-33

[39] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients) [J].

Lepretre, Stephane ;

Aurran, Therese ;

Mahe, Beatrice ;

Cazin, Bruno ;

Tournihlac, Olivier ;

Maisonneuve, Herve ;

Casasnovas, Olivier ;

Delmer, Alain ;

Leblond, Veronique ;

Royer, Bruno ;

Corront, Brigitte ;

Chevret, Sylvie ;

Delepine, Roselyne ;

Vaudaux, Sandrine ;

Van Den Neste, Eric ;

Bene, Marie-Christine ;

Cymbalista, Florence ;

Feugier, Pierre .

BLOOD, 2009, 114 (22) :225-225

[40] Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease [J].

Lin, Thomas S. ;

Ruppert, Amy S. ;

Johnson, Amy J. ;

Fischer, Beth ;

Heerema, Nyla A. ;

Andritsos, Leslie A. ;

Blum, Kristie A. ;

Flynn, Joseph M. ;

Jones, Jeffrey A. ;

Hu, Weihong ;

Moran, Mollie E. ;

Mitchell, Sarah M. ;

Smith, Lisa L. ;

Wagner, Amy J. ;

Raymond, Chelsey A. ;

Schaaf, Larry J. ;

Phelps, Mitch A. ;

Villalona-Calero, Miguel A. ;

Grever, Michael R. ;

Byrd, John C. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6012-6018

← 1 2 3 4 5 6 7 →